It took until the fall of 2020 for Medicare to consistently pay an adequate amount for CAR-T therapy. Now that same agonizing process awaits a raft of promising gene therapies in the pipeline – with lives in the balance – unless policymakers take action.
Other featured articles
Legalizing Marijuana, once a Pipe Dream on Capitol Hill, Takes an Important Step Forward
Rosalie Liccardo Pacula writes about strengths and weakness in the MORE Act along with additional policy ideas that could strengthen regulation and better protect consumers.
Evidence of COVID-19’s Impact on K-12 Education Points to Critical Areas of Intervention
Survey data shows remote learners are suffering from lower-quality learning, less quantity and quality of interactions with teachers, and less social interaction with peers.